Multiple Sclerosis, Primary Progressive Clinical Trial
Official title:
Longitudinal Study of Cognition in Primary Progressive Multiple Sclerosis: a Cohort Study
Cognitive impairment is nowadays more and more recognized as an important feature of the multiple sclerosis (MS) disease. Cognitive disorders frequency in MS is estimated between 40 and 60%. Cognitive impairment affects quality of life and vocational status in MS patients. Until recently, little information was available on the cognitive dysfunction and their evolution that occur in primary progressive multiple sclerosis (PPMS) as compared with relapsing-remitting MS (RRMS). In PPMS pathological studies have shown the importance of cortical demyelination and meningeal inflammation suggesting that the GM alteration could play a major role in the cognitive impairment in this phenotype. The cognitive evolution and the brain tissue alteration at the origin of these difficulties remain poorly understood in PPMS. The use of new techniques for morphological and functional MRI can study the contribution of diffuse White Matter (WM) alteration (probably through disconnexion of relevant network) and diffuse Grey matter (GM) alterations in the cerebral cortex and other structures (the hippocampi, the cerebellum, and the thalami) in cognitive impairment in PPMS patients and on their evolution.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04544449 -
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
|
Phase 3 | |
| Completed |
NCT06436131 -
The Effects of In-phase Bilateral Exercise in People With Progressive Multiple Sclerosis
|
N/A | |
| Recruiting |
NCT04918225 -
Motor Asymmetry in Progressive Multiple Sclerosis Patients
|
||
| Completed |
NCT02913157 -
Hydroxychloroquine in Primary Progressive Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT01982942 -
Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
|
Phase 2 | |
| Recruiting |
NCT05204459 -
MS-ResearchBiomarkerS
|
||
| Completed |
NCT05663853 -
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
|
||
| Completed |
NCT01194570 -
A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
|
Phase 3 | |
| Completed |
NCT02305264 -
Imaging of Intracerebral Inflammation in MS
|
N/A | |
| Completed |
NCT03679468 -
Improving Cognition in People With Progressive Multiple Sclerosis Using Aerobic Exercise and Cognitive Rehabilitation
|
N/A | |
| Recruiting |
NCT05496881 -
Exercise Effects in Multiple Sclerosis
|
N/A | |
| Completed |
NCT02506751 -
Open-label Study of Liothyronine in MS
|
Phase 1 | |
| Temporarily not available |
NCT02606929 -
Use of Well Known Drugs for New Destination - MS Improvement (MSNT)
|
Phase 0 | |
| Completed |
NCT03424538 -
The Effect of Neurorehabilitation Therapy on Postural Control, Mobility and Quality of Life in Multiple Sclerosis Patients
|
N/A | |
| Completed |
NCT04545372 -
Aerobic Exercises for Multiple Sclerosis
|
N/A | |
| Recruiting |
NCT05122559 -
Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT02988401 -
Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis
|
Phase 1/Phase 2 | |
| Completed |
NCT02632591 -
Use on Human Beings of Mix of Known Drugs for New Destination - MS Treatment
|
Phase 1 | |
| Completed |
NCT01917019 -
A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis
|
Phase 3 | |
| Completed |
NCT01433497 -
Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis
|
Phase 3 |